End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,818 INR | +1.32% | +1.58% | +8.32% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 68.01 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.32% | 1.12B | B+ | ||
-18.67% | 8.22B | B+ | ||
+48.66% | 3.73B | C+ | ||
-8.06% | 2.46B | - | ||
-38.71% | 2.46B | B- | ||
-8.84% | 2.36B | B- | ||
-9.02% | 1.78B | C- | ||
-19.29% | 1.52B | A- | ||
-40.78% | 1.21B | C+ | ||
-12.27% | 1.09B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- METROPOLIS Stock
- Ratings Metropolis Healthcare Limited